The Journal of the American Medical Association (JAMA) published a controversial meta-analysis suggesting that people who are overweight (a body mass index [BMI] of 25-...

Dr. Diana Guthrie, winner of the AADE Living Legend Award, on controlled breathing and supplements for people with diabetes…

(S)he said what?!?

By Hannah Deming Lately, the use of basal insulins (such as Lantus and Levemir) in combination with GLP-1 agonists (such as Byetta , Victoza , and Bydureon ) has been...

Earlier this month, the American Diabetes Association (ADA) and the co-chairs of the Senate Diabetes Caucus, Senator Susan Collins (R-ME) and Jeanne Shaheen (D-NH),...

(S)he said what?!?

Gary Scheiner shares how to make your blood glucose data work for you.

On October 18, Reata and Abbott stopped their phase 3, 2,000-patient BEACON trial for the drug bardoxolone methyl, the most promising candidate in development for the...

(S)he said what?!? Last updated September 13, 2012.

In May, Johnson & Johnson submitted its SGLT-2 inhibitor canagliflozin for approval in the US. On average, the FDA takes about ten months to review applications for...

Visiting your healthcare team? Kerri Sparling highlights the right questions to ask.

On November 14, the European Commission approved AstraZeneca and Bristol-Myers Squibb’s Forxiga (dapagliflozin) for type 2 diabetes throughout the European Union...

In January, the American Heart Association and American Diabetes Association published a statement giving their joint recommendations for the primary prevention of CVD...

Do you ever wonder why there aren’t cheaper “generic” insulin products available? This may soon change as the patents for branded insulin begin to expire. In fact, the...

The FDA impresses us at The Diabetes Mine Innovation Summit. Plus, sleek new software for downloading data to the cloud.

Recently, Asante announced two important collaborations for downloading its new Snap insulin pump , which features 300 unit pre-filled insulin cartridges and a unique...

The FDA released its final guidance earlier this fall on the types of mobile medical apps it will regulate. As expected, the FDA will have oversight on mobile medical...

Five key insights from April’s big-deal artificial pancreas meeting in Washington, DC.

The dangers of competitive bidding for diabetes care and what you can do. Plus, win a year’s worth of any brand of test strips!

What do Michelle Obama, soda, and cities have in common? Our top five patient takeaways from PHA this year.